DXSE:F:F-Xtrackers Stoxx Europe 600 Health Care Swap UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 207.45

Change

+1.65 (+0.80)%

Market Cap

N/A

Volume

89.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-19 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

+1.60 (+0.28%)

USD 101.74B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.45 (-0.86%)

USD 101.37B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 96.03B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.07 (-0.44%)

USD 57.02B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 53.72B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-2.60 (-1.10%)

USD 45.80B
0ZC:F Zscaler Inc

-1.10 (-0.49%)

USD 37.92B
BSND:F Danone SA

-0.20 (-1.37%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-0.46 (-0.36%)

USD 24.77B

ETFs Containing DXSE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.42% 35% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.42% 35% F 46% F
Trailing 12 Months  
Capital Gain -10.81% 14% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.81% 13% F 34% F
Trailing 5 Years  
Capital Gain 24.76% 38% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.76% 38% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain 9.42% 69% C- 65% D
Dividend Return 9.42% 66% D+ 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.99% 72% C 93% A
Risk Adjusted Return 104.81% 94% A 94% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike